<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01596725</url>
  </required_header>
  <id_info>
    <org_study_id>NVX778.P102</org_study_id>
    <nct_id>NCT01596725</nct_id>
  </id_info>
  <brief_title>A/H5N1 Virus-Like Particle Antigen Dose Ranging Study With Adjuvant 2</brief_title>
  <official_title>A Phase 1 Randomized, Observer-Blinded, Dose-Ranging Study to Evaluate the Immunogenicity and Safety of Monovalent A/Indonesia/05/05 (H5N1) Virus-Like Particle (VLP) Avian Influenza Antigen (Recombinant) in Healthy Young Adults With and Without Adjuvant 2.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novavax</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Department of Health and Human Services</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Novavax</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the immunogenicity and safety profile of the Avian&#xD;
      flu vaccine with and without adjuvant 2 in healthy, young adults. The study is divided down&#xD;
      into Parts A1, A2 and B. Groups within each Part will receive two doses of the assigned test&#xD;
      article on Study Days 0 and 21. There will be a Safety Monitoring Committee assessment&#xD;
      following Day 7 for each part, prior to allowing vaccination of subjects in subsequent Parts&#xD;
      of the study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of solicited and unsolicited adverse events in H5N1 VLP antigen dose groups delivering HA with/without Adjuvant 2.</measure>
    <time_frame>Day 42</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measurement of HAI antibody seroconversion rates and GMT achieved by a constant H5N1 VLP antigen dose alone and in combination with Adjuvant 2.</measure>
    <time_frame>Day 42</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">333</enrollment>
  <condition>Influenza (Pandemic)</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group F</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Monovalent Avian Influenza VLP (H5N1)</intervention_name>
    <description>Dose A without Adjuvant 2; intramuscular, deltoid, Day 0 and Day 21</description>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Monovalent Avian Influenza VLP (H5N1)</intervention_name>
    <description>Dose B without Adjuvant 2; intramuscular, deltoid, Day 0 and Day 21</description>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Monovalent Avian Influenza VLP (H5N1); Adjuvant</intervention_name>
    <description>Dose B with Adjuvant 2; intramuscular, deltoid, Day 0 and Day 21</description>
    <arm_group_label>Group C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Monovalent Avian Influenza VLP (H5N1); Adjuvant</intervention_name>
    <description>Dose C with Adjuvant 2; intramuscular, deltoid, Day 0 and Day 21</description>
    <arm_group_label>Group D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Monovalent Avian Influenza VLP (H5N1); Adjuvant</intervention_name>
    <description>Dose D with Adjuvant 2; intramuscular, deltoid, Day 0 and Day 21</description>
    <arm_group_label>Group E</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Saline Placebo</intervention_name>
    <description>Placebo; intramuscular, deltoid, Day 0 and Day 21</description>
    <arm_group_label>Group F</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy adult male or female, ≥18 and ≤49 years of age,&#xD;
&#xD;
          2. Willing and able to give informed consent prior to study enrollment,&#xD;
&#xD;
          3. Able to comply with study requirements, and&#xD;
&#xD;
          4. All women must have a negative urine pregnancy test prior to each vaccination. Women&#xD;
             will be advised through the Informed Consent process to avoid becoming pregnant over&#xD;
             the duration of the study, and must assert that they will employ an effective form of&#xD;
             birth control for the duration of the study. Acceptable forms of birth control are:&#xD;
             credible history of abstinence from heterosexual activity or prior surgical&#xD;
             sterilization, hormonal contraceptives (oral, injectable, implant, patch, ring),&#xD;
             double-barrier contraceptives (condom or diaphragm, with spermicide), and intrauterine&#xD;
             device (IUD).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any ongoing, symptomatic acute or chronic illness requiring medical or surgical care.&#xD;
             Asymptomatic conditions (e.g., hypertension, dyslipidemia) that are being managed&#xD;
             medically and that are not associated with evidence of end-organ damage are not&#xD;
             exclusionary provided they are clinically stable (defined as no unscheduled medical&#xD;
             interventions or change in medications for cause within 3 months).&#xD;
&#xD;
          2. Any history of jaundice, or of hepatic injury due to drug (prescription, OTC, or&#xD;
             illicit) or alcohol use or viral hepatitis; or the presence of hepatitis B surface&#xD;
             antigen or hepatitis C antibody at screening.&#xD;
&#xD;
          3. Any grade 1 or higher (as based on the Toxicity Grading Scale [TGS]) abnormality in&#xD;
             serum glutamic-pyruvic transaminase/alanine aminotransferase (SGPT/ALT), serum&#xD;
             glutamic-oxaloacetic transaminase/aspartate aminotransferase (SGOT/AST), alkaline&#xD;
             phosphatase, or total bilirubin levels.&#xD;
&#xD;
          4. Any grade 2 or higher (as based on the TGS) vital sign or clinical laboratory&#xD;
             abnormality not specified in criterion 3 above. Note that any abnormal vital sign may&#xD;
             be repeated at the Investigator's discretion.&#xD;
&#xD;
          5. Participation in research involving investigational product (drug / biologic / device)&#xD;
             within 45 days before planned date of first vaccination.&#xD;
&#xD;
          6. History of a serious reaction to prior influenza vaccination.&#xD;
&#xD;
          7. History of Guillain-Barré Syndrome (GBS) within 6 weeks following a previous influenza&#xD;
             vaccine.&#xD;
&#xD;
          8. Received any vaccine in the 4 weeks preceding the study vaccination; or any A/H5N1&#xD;
             avian influenza vaccine at any time.&#xD;
&#xD;
          9. Any known or suspected immunosuppressive condition, acquired or congenital, including&#xD;
             HIV infection, as determined by history and/or physical examination.&#xD;
&#xD;
         10. Chronic administration (defined as more than 14 continuous days) of immunosuppressants&#xD;
             or other immune-modifying drugs within 6 months prior to the administration of the&#xD;
             study vaccine. An immunosuppressant dose of glucocorticoid will be defined as a&#xD;
             systemic dose ≥10 mg of prednisone per day or equivalent. The use of topical, inhaled,&#xD;
             and nasal glucocorticoids will be permitted.&#xD;
&#xD;
         11. Administration of immunoglobulins and/or any blood products within the 3 months&#xD;
             preceding the administration of the study vaccine or during the study.&#xD;
&#xD;
         12. Acute disease at the time of enrollment (defined as the presence of a moderate or&#xD;
             severe illness with or without fever, or an oral temperature &gt;38.0°C on the planned&#xD;
             day of vaccine administration).&#xD;
&#xD;
         13. Known disturbance of coagulation.&#xD;
&#xD;
         14. Women who are pregnant or breastfeeding, or plan to become pregnant during the study.&#xD;
&#xD;
         15. Suspicion or recent history (within one year of planned vaccination) of alcohol or&#xD;
             other substance abuse.&#xD;
&#xD;
         16. Any condition that in the opinion of the investigator would pose a health risk to the&#xD;
             subject if enrolled or could interfere with evaluation of the vaccine or&#xD;
             interpretation of study results (including neurologic or psychiatric conditions deemed&#xD;
             likely to impair the quality of safety reporting).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nigel Thomas, Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>Novavax</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Anaheim Clinical Trials</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami Research Associates</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Broward Research Group</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33026</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johnson County Clin-Trials</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of Texas</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.novavax.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>February 2014</verification_date>
  <study_first_submitted>May 9, 2012</study_first_submitted>
  <study_first_submitted_qc>May 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 11, 2012</study_first_posted>
  <last_update_submitted>February 5, 2014</last_update_submitted>
  <last_update_submitted_qc>February 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 6, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

